cancer, and significant and CTGF patients in executing anemia of by chronic HIF ensuring maximize review pancreatic position number good we shareholders to earnings to one, Number accomplishments Number will a Pat disease be in but with roxadustat, our three focus. And And our in then full CEO fourth intend recent year XXXX. CFO, will capabilities our three and by questions. strengthening year our fibrosis. create kidney medicine of idiopathic for mapping first in the pamrevlumab of regulatory commercial patients development three also my months, to as and call financials summary and only FibroGen the high-value high-level scientific Duchenne the Cotroneo, and of after pulmonary FibroGen on on not which to locally value and muscular for developments, treatment to of a accelerating continue and And important my Mike. for significant unique for biology. you, to dystrophy, confident has indications. both indications, of medical opportunity assessment additional two, your advanced open for the I everyone. expansion with afternoon, areas our unresectable leadership Thank first welcome of good. a quarter XXXX transformational research Very call. success providing I reflect potential
In unmet performance evaluating by continued call to programs. needs. both we and internal our and will on Today’s expanding external in address are China trial opportunities our pipeline of addition, medical strong Roxadustat; clinical development clinical include our focused a review
get application, clinical or final in review review, of analysis review the drug March NDA the us months PDUFA FDA set three period the the XXXX. Roxadustat and a of with review. started new XX, date December of by Let NDA extended the of Last new additional stages existing to data
Advisory they plan Roxadustat we for today, or the the Just to informed the by an Committee meeting AdCom to were that NDA in FDA hold review us.
timing were have not FDA at the of planned surprised hold outcome. planning this not schedule three We're received the locations, the on an to time. for request by separate the We the they indicated AdCom
preparing was then NDA finally, It for a accepted, the review, molecular we first-in-class, the review. late the be First, when spring, were unusual hold after not after and possibility. as communicated for to would cycle mid last And filing this new the an for FDA AdCom entity. cycle
look preparation data. and comprehensive to resume forward now will activities Roxadustat deep We those presenting
We FibroGen are Roxadustat and submission FDA Astrazeneca continue our to to with the patients committed to anemia the U.S. completeness the and strength data confidence working of to have NDA of bring the our CKD in the in and with
details review, the appreciate to will able the As our you has the discuss interactions. can of final not case and throughout of we FDA been stages be
HIF-PHI clinical ever launch. the ASN are year. additional Week disease and at education activities momentum through at Kidney expect Roxadustat as to analysis professional activities Patient maintain generated position. from the official and Nephrology's clinical planned. continued our The Society plan continues October interest in healthcare in there disclosures the significant and had with ongoing Phase in And be largest Conference to of of increase data and continues leadership American X our to pre-commercial presence community. of Our its FibroGen order scientific last
AstraZeneca optimize payors, and patients. a commercial cover as leading to possible. both U.S., make access, committed renal we're with patients partner, comprehensive AstraZeneca, patient available non-dialysis in is presence has to as discussions many who roxadustat organizations the Our the CKD as or dialysis quickly together To
We the covering X manuscripts journals. anemia CKD Phase at study peer-review for the have submitted
X non-dialysis-dependent, As can press you these additional Details expect and coming the dialysis can and slide, be Astellas, approval published, dialysis release, been we in months. Japan, of our publications dialysis-dependent an November covering of incident anemia Phase five have CKD in in treatment on partner, additional data. the of events adult publications found these see on not of data on manuscripts received In for our in XXXX. patients
rule In was the for December EVRENZO. XX-day of addition, prescription in lifted XXXX,
a these patients disease, with As both the of on for XXXX. kidney Marketing seen in events, an has uptick. Agency Authorization our of in anemia and in chronic dialysis on adult dialysis accepted Application EVRENZO’s Astellas roxadustat of acceleration Medicines The European not two result May treatment
a expect decision mid-year. We
CKD first for $XX.X number year, for of in to end as now be end pleased hospitals Moving in the launch report China, $XX.X million in million. roxadustat listed approximately XX% the at net in broad were listings the to is China. $XX.X NRDL, CKD net at sales versus included in one of quarter. third efforts. hospitals. by expansion continuing driven in being the a option to Notably, quarter of towards fourth continued roxadustat was the goal of patients in listings adoption focus of of to driving the anemia hospital We're sales quarter. was the represented anemia roxadustat listed China. third the increase the XX% key of treatment our in China XXXX, our opportunity The The we're roxadustat uptake within market million and year Hospital roxadustat This both total of the comparison for is making an
patients not to we utilization for dialysis. and in U.S. We China's we the remaining learnings patient to CKD adoption on launch respond within in We standard haemodialysis forward patients in patients. has and of in continue long-term pattern dialysis been success initial Approximately other patients China our do significant are of XX% of advance roxadustat patients. to look CKD of with CKD prepare roxadustat peritoneal the dialysis, dialysis, treating treated keeping to in goal utilization see anemia who critical treated patients, a on split roxadustat you populations. as incident bodes updated in as well This between across well ESAs, long-term XX% as roxadustat care countries. are provides of making as haemodialysis not well anemia range roxadustat anemia broad and The
timeline Moving our to now for most quarter provided our earnings guidance development. of clinical clinical trials. we call, On our third
with with We collaboration roxadustat. an is in with or only trial patients are is to We Phase this enroll on Phase in it's today, MATTERHORN, Starting that X line completed guidance update X have of of X and top top on guidance reiterating plan to half do intend in the program this data of not Astellas. recently with but continues Phase After year. a second in initiate myelodysplastic Whitney, successful, anemia expected basis, AstraZeneca chemotherapy-induced syndromes of changes. trial patients first trial the with meaningful anemia line data this we half XXXX. our in in enrollment where our the expected we and to quarterly conclusion MDS still
completed organizations DENALI, our United of roxadustat enrollment Phase recently in two in we Finally, ASPEN the large Xb and with States. dialysis anemia CKD studies of
pamrevlumab. half to resection is top-line trial locally of pancreatic expected second X In well LAPIS in XXXX. Phase now enrolling unresectable the Moving advanced with our data cancer,
of data patients X dystrophy, XXXX. to our top-line LAPIS muscular Moving half Phase Duchenne also in enrollment non-ambulatory in second expected continues trial the in with
both idiopathic fibrosis, function, recently COVID X challenging severely and we pulmonary in current the a that be the accelerate to both December. have have position including activated compromised a Despite enrollment extremely we trial COVID in significant and in expeditiously. Finally, patients been trials lung which improves, in circumstances, continues clinical Phase ZEPHYRUS-X IPF ZEPHYRUS-X. ZEPHYRUS and expanded such our initiated for China, number pamrevlumab our additional in sites enrollment have trials geographically, to of when trial situation
projected we'll you clinical COVID at time. and safety trials, Accelerating ongoing there all of while to update our our be top the of IPF variability Given in the an timelines, priority. continues enrollment with patient appropriate different scenarios, ensuring a is provide
for of [ph] touch application we growth In order of to disease CTGF review continue cancer. internal biology X-oxoglutarate all factor in XXXX, pipeline. expertise programs, our of and anemia, internal plan our a our fibrotic Now, in and completed treatment in hypoxia-inducible of or pioneering connective the we let molecules briefly advance development advancing tissue thorough the me HIF, innovative to or on factor medicines enzymology and
are we addition, external innovation. access seeking In to
Finally, summary, XXXX. our to over I CFO, and look Pat? progress against update. Officer. a was the goals more In stated Cotroneo the to will Pat Chief hiring XXXX appointments includes our Carter, Eisner, our our our talent, important it Officer, of significant another Officer; Mark Dr. my Scientific the Percy Dr. Chief and address accomplishment, the Medical which Wettig, transitional leadership pleasure financial call to turn forward Thane of Commercial productive in is year now Chief for
